Congruent with these psychopharmacological conclusions and the types of experience-dependent plasticity that have been observed in this system (see Sections 1A and 2A), KOR antagonists have shown preclinical potential in the treatment of depression- and addiction-like behaviors. Here, OPRK1 is linked to major depressive disorder.